QLGN vs. LPTX, IMCC, MBRX, BIVI, MRKR, BCDA, GOVX, GELS, PHIO, and HCWB
Should you be buying Qualigen Therapeutics stock or one of its competitors? The main competitors of Qualigen Therapeutics include Leap Therapeutics (LPTX), IM Cannabis (IMCC), Moleculin Biotech (MBRX), BioVie (BIVI), Marker Therapeutics (MRKR), BioCardia (BCDA), GeoVax Labs (GOVX), Gelteq (GELS), Phio Pharmaceuticals (PHIO), and HCW Biologics (HCWB). These companies are all part of the "pharmaceutical products" industry.
Qualigen Therapeutics vs. Its Competitors
Qualigen Therapeutics (NASDAQ:QLGN) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.
3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are owned by institutional investors. 1.8% of Qualigen Therapeutics shares are owned by insiders. Comparatively, 7.5% of Leap Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Qualigen Therapeutics' return on equity of 0.00% beat Leap Therapeutics' return on equity.
Leap Therapeutics has a consensus price target of $3.38, suggesting a potential upside of 1,095.11%. Given Leap Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Leap Therapeutics is more favorable than Qualigen Therapeutics.
Qualigen Therapeutics has a beta of -0.15, suggesting that its stock price is 115% less volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of -0.21, suggesting that its stock price is 121% less volatile than the S&P 500.
In the previous week, Qualigen Therapeutics had 1 more articles in the media than Leap Therapeutics. MarketBeat recorded 1 mentions for Qualigen Therapeutics and 0 mentions for Leap Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.50 beat Leap Therapeutics' score of 0.00 indicating that Qualigen Therapeutics is being referred to more favorably in the media.
Qualigen Therapeutics has higher revenue and earnings than Leap Therapeutics.
Summary
Qualigen Therapeutics beats Leap Therapeutics on 6 of the 11 factors compared between the two stocks.
Get Qualigen Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding QLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Qualigen Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:QLGN) was last updated on 9/9/2025 by MarketBeat.com Staff
Free QLGN Stock Alerts